These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 28838807)

  • 1. Skeletal health in breast cancer survivors.
    Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
    Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
    Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
    Waqas K; Lima Ferreira J; Tsourdi E; Body JJ; Hadji P; Zillikens MC
    J Bone Oncol; 2021 Jun; 28():100355. PubMed ID: 33948427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis management in patients with breast cancer: EMAS position statement.
    Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
    Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.
    Bassatne A; Bou Khalil A; Chakhtoura M; Arabi A; Van Poznak C; El-Hajj Fuleihan G
    Metabolism; 2022 Mar; 128():154962. PubMed ID: 34958816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
    Gaudio A; Xourafa A; Rapisarda R; Castellino P
    Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
    Hadji P; Aapro MS; Body JJ; Gnant M; Brandi ML; Reginster JY; Zillikens MC; Glüer CC; de Villiers T; Baber R; Roodman GD; Cooper C; Langdahl B; Palacios S; Kanis J; Al-Daghri N; Nogues X; Eriksen EF; Kurth A; Rizzoli R; Coleman RE
    J Bone Oncol; 2017 Jun; 7():1-12. PubMed ID: 28413771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
    Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
    Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and treatment of side-effects of systemic treatment: bone loss.
    Body JJ
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii180-5. PubMed ID: 20943612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of bone loss due to endocrine therapy during cancer treatment.
    Khan MI
    Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopenia and osteoporosis in women with breast cancer.
    Ramaswamy B; Shapiro CL
    Semin Oncol; 2003 Dec; 30(6):763-75. PubMed ID: 14663777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
    Kyvernitakis I; Kann PH; Thomasius F; Hars O; Hadji P
    Bone; 2018 Sep; 114():109-115. PubMed ID: 29908297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.